Postoperative proliferative vitreoretinopathy development is linked to vitreal CXCL5 concentrations

Area of Science:

• Ophthalmology
• Molecular Biology
• Immunology

Background:

• Postoperative proliferative vitreoretinopathy (PVR) is a significant complication following rhegmatogenous retinal detachment (RRD) surgery.
• The specific molecular changes driving the de novo development of PVR remain incompletely understood.
• Identifying predictive biomarkers is crucial for developing effective preventive strategies.

Purpose of the Study:

• To investigate preoperative vitreous fluid (VF) cytokine and chemokine profiles in patients undergoing vitrectomy for primary RRD.
• To identify potential biomarkers associated with the development of postoperative PVR.
• To explore the role of specific biomarkers in the pathogenesis of PVR.

Main Methods:

• Vitreous fluid samples were collected from 65 eyes undergoing vitrectomy for primary RRD without preoperative PVR.
• Multiplex bead analysis was used to quantify the concentrations of 43 cytokines and chemokines in VF.
• Statistical analysis, including Holm's correction, compared biomarker concentrations between eyes that developed postoperative PVR and those that did not.

Main Results:

• 18.5% of eyes (12 out of 65) developed PVR within six months post-surgery.
• Twelve cytokines and chemokines showed statistically significant concentration differences (p < 0.05) between groups.
• CXCL5 was the only cytokine with a robustly significant difference in VF concentration, identifying it as a strong predictor of postoperative PVR development.

Conclusions:

• CXCL5 is a potent biomarker for the de novo development of postoperative PVR.
• The findings suggest CXCL5's involvement in PVR pathogenesis.
• CXCL5 may serve as a target for developing novel preventive therapies for PVR.